Initial clinical outcomes for prostate cancer patients undergoing adjuvant or salvage proton therapy after radical prostatectomy

References

• Thompson IM, Valicenti RK, Albertsen P, et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO guideline. J Urol. 2013;190(2):441–449.
   PubMed Web of Science ®Google Scholar
• Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012;380(9858):2018–2027.
   PubMed Web of Science ®Google Scholar
• Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181(3):956–962.
   PubMed Web of Science ®Google Scholar
• Wiegel T, Bartkowiak D, Bottke D, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol. 2014;66(2):243–250.
   PubMed Web of Science ®Google Scholar
• Hackman G, Taari K, Tammela TL, et al. Randomised trial of adjuvant radiotherapy following radical prostatectomy versus radical prostatectomy alone in prostate cancer patients with positive margins or extracapsular extension. Eur Urol. 2019;76(5):586–595.
   PubMed Web of Science ®Google Scholar
• Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. JCO. 2007;25(15):2035–2041.
   PubMed Web of Science ®Google Scholar
• Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008;299(23):2760.
   PubMed Web of Science ®Google Scholar
• Shipley WU, Seiferheld W, Lukka HR, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med. 2017;376(5):417–428.
   PubMed Web of Science ®Google Scholar
• Carrie C, Hasbini A, de Laroche G, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2016;17(6):747–756.
   PubMed Web of Science ®Google Scholar
• Pollack A, Karrison TG, Balogh AG, Jr, et al. Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiotherapy: the NRG Oncology/RTOG 0534 SPPORT Trial. Int J Radiat Oncol Biol Phys. 2018;102(5):1605.
   Web of Science ®Google Scholar
• Deville C, Vapiwala N, Hwang WT, et al. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy. Int J Radiat Oncol Biol Phys. 2012;82(4):1389–1396.
   PubMed Web of Science ®Google Scholar
• Deville C, Jr, Jain A, Hwang WT, et al. Initial report of the genitourinary and gastrointestinal toxicity of post-prostatectomy proton therapy for prostate cancer patients undergoing adjuvant or salvage radiotherapy. Acta Oncol. 2018;57(11):1506–1514.
   PubMed Web of Science ®Google Scholar
• Santos PMG, Barsky AR, Hwang WT, et al. Comparative toxicity outcomes of proton beam therapy versus intensity-modulated radiotherapy for prostate cancer in the post-operative setting. Cancer. 2019;125(23):4278–4293.
   PubMed Web of Science ®Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT00969111. [cited 2019 Oct 27].
   Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT03570827. [cited 2019 Oct 27].
   Google Scholar
• Koerber SA, Katayama S, Sander A, et al. Prostate bed irradiation with alternative radio-oncological approaches (PAROS) - a prospective, multicenter and randomized phase III trial. Radiat Oncol. 2019;14(1):122.
   PubMedGoogle Scholar
• Michalski JM, Lawton C, El Naqa I, et al. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010;76(2):361–368.
   PubMed Web of Science ®Google Scholar
• Lawton CA, Michalski J, El-Naqa I, et al. RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2009;74(2):383–387.
   PubMed Web of Science ®Google Scholar
• Kirk ML, Tang S, Zhai H, et al. Comparison of prostate proton treatment planning technique, interfraction robustness, and analysis of single-field treatment feasibility. Pract Radiat Oncol. 2015;5(2):99–105.
   PubMed Web of Science ®Google Scholar
• International Commission on Radiation Units and Measurements. Prescribing, recording, and reporting proton-beam therapy (ICRU Report 78). Oxford: Oxford University Press; 2007. (vol. 7, no. 2). Chapter 6: Treatment Planning; p. 96–99.
   Google Scholar
• Tendulkar RD, Agrawal S, Gao T, et al. Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. JCO. 2016;34(30):3648–3654.
   PubMed Web of Science ®Google Scholar
• Carrie C, Magné N, Burban-Provost P, et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 2019.
   Web of Science ®Google Scholar